Abstract. Background: Treatment of mild-moderate Alzheimer's disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by ...
Moussa et al. Journal of Neuroinflammation (2017) 14:1 DOI 10.1186/s12974-016-0779-0
RESEARCH
Open Access
Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease Charbel Moussa1* , Michaeline Hebron1, Xu Huang1, Jaeil Ahn2, Robert A. Rissman3, Paul S. Aisen4 and R. Scott Turner5
Abstract Background: Treatment of mild-moderate Alzheimer’s disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Aβ40 levels and activities of daily living (ADL) scores. Methods: For this retrospective study, we examined banked CSF and plasma samples from a subset of AD subjects with CSF Aβ42
